All In Biotech

Drug Trial Radar · NCT02718417

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER JAVELIN OVARIAN 100

Last checked: Nov 20, 2026Latest source record: Jul 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 998 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

998

Actual

Start

May 19, 2016

Primary completion

Sep 7, 2018

Study completion May 16, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.

Conditions

  • Ovarian Cancer

Interventions

  • carboplatinDrug

    Given Q3W during chemotherapy phase

  • paclitaxelDrug

    Investigator choice of weekly or Q3W during chemotherapy phase

  • AvelumabDrug

    Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion

  • AvelumabDrug

    Given as single agent in maintenance portion Q2W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Baseline to progression of disease or discontinuation from the study or death, whichever occurred first (maximum duration of 27 months)

Locations

319 sites in 25 countries. Site status is shown where the registry gives one.

  • Alabama Oncology

    Alabaster, Alabama

  • Alabama Oncology

    Bessemer, Alabama

  • Alabama Oncology, Bruno Cancer Center

    Birmingham, Alabama

  • Alabama Oncology

    Birmingham, Alabama

  • Alabama Oncology

    Birmingham, Alabama

  • Alabama Oncology

    Birmingham, Alabama

  • Alabama Oncology

    Birmingham, Alabama

  • Arizona Oncology Associates, PC - HAL

    Phoenix, Arizona

  • Arizona Oncology Associates, PC - HAL

    Phoenix, Arizona

  • Arizona Oncology Associates, PC - HAL

    Scottsdale, Arizona

  • Arizona Oncology Associates, PC - HAL

    Tempe, Arizona

  • Arizona Oncology Associates, PC-HOPE

    Tucson, Arizona

  • Arizona Oncology Associates, PC-HOPE

    Tucson, Arizona

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Highlands Oncology Group

    Rogers, Arkansas

  • Oso HomeCare

    Irvine, California

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California

  • Medical Center, Cedars-Sinai

    Los Angeles, California

  • Gynecologic Oncology Associates

    Newport Beach, California

  • Chao Family Comprehensive Cancer Center

    Orange, California

  • Hematology-Oncology Medical Group of Orange County

    Orange, California

  • Medical Oncology Care Associates

    Orange, California

  • St. Joseph Hospital of Orange

    Orange, California

  • The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange

    Orange, California

  • UC Irvine Health

    Orange, California

  • University of California, Irvine/UC Irvine Health

    Orange, California

  • California Pacific Medical Center - Medical Office Building

    San Francisco, California

  • California Pacific Medical Center - Van Ness Campus

    San Francisco, California

  • California Pacific Medical Center - Davies Campus

    San Francisco, California

  • Bryan Hemming Cancer Care Center - California Pacific Medical Center

    San Francisco, California

  • California Pacific Medical Center - Pacific Heights Outpatient Pharmacy

    San Francisco, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • California Pacific Medical Center-Research Institute

    San Francisco, California

  • Palo Alto Medical Foundation Group

    San Francisco, California

  • Sansum Clinic

    Santa Barbara, California

  • Sansum Clinic

    Solvang, California

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Boulder, Colorado

  • Rocky Mountain Cancer Centers

    Lakewood, Colorado

  • C/O Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut

Showing 40 of 319 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.